Etoposido
Etoposidoa, VP-16 bezala ere ezaguna, podofilina erdiintetiko bat da, Podophyllum landaretik eratorria. Tumore-zelulen ugalketa inhibitzeko duen gaitasunagatik minbizi mota batzuk tratatzeko erabiltzen dute.
Etoposido | |
---|---|
Formula kimikoa | C29H32O13 |
SMILES kanonikoa | 2D eredua |
SMILES isomerikoa | C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O |
MolView | 3D eredua |
Mota | [[(5S,5aR,8aR,9R)-5-[(7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-isobenzofuro[6,5-f][1,3]benzodioxol-8-one|(5S,5aR,8aR,9R)-5-[(7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-isobenzofuro[6,5-f][1,3]benzodioxol-8-one]] (en) eta [[(8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-isobenzofuro[6,5-f][1,3]benzodioxol-8-one|(8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-isobenzofuro[6,5-f][1,3]benzodioxol-8-one]] (en) |
Masa molekularra | 588,184 Da |
Erabilera | |
Konposatu aktiboa | Toposar (en) eta Etopophos (en) |
Tratatzen du | Neuroblastoma, testicular cancer (en) , garuneko minbizi, mikosi fungoide, trophoblastic neoplasm (en) , Ewingen sarkoma, histiozitosi, lung benign neoplasm (en) , prostatako minbizi, umetokiko minbizi, Kaposiren sarkoma, acute myeloid leukemia (en) , errabdomiosarkoma, maxkuriko minbizi, linfoma, germ cell cancer (en) , B-cell lymphoma (en) , ez-Hodgkin linfoma, testicular malignant germ cell cancer (en) , Hezur sarkoma, neuroblastoma, susceptibility to (en) , diffuse large B-cell lymphoma (en) , testicular cancer (en) eta lung small cell carcinoma (en) |
Interakzioak | ziklosporina |
Elkarrekintza | DNA topoisomerase II alpha (en) |
Hartzeko bidea | intravenous infusion and defusion (en) eta aho emate |
Haurdunaldia | Australian pregnancy category D (en) eta US pregnancy category D (en) |
Rola | DNA polymerase inhibitors (en) , topoisomerase inhibitor (en) , phytogenic antineoplastic agents (en) , topoisomerase II inhibitor (en) , developmental toxicant (en) , kantzerigeno eta farmako esentzial |
Identifikatzaileak | |
InChlKey | VJJPUSNTGOMMGY-MRVIYFEKSA-N |
CAS zenbakia | 33419-42-0 |
ChemSpider | 33510 |
PubChem | 36462 |
Gmelin | 4911 |
ChEMBL | CHEMBL44657 |
EC zenbakia | 251-509-1 |
ECHA | 100.046.812 |
MeSH | D005047 |
RxNorm | 4179 |
UNII | 6PLQ3CP4P3 |
NDF-RT | N0000146478 |
KEGG | C01576 eta D00125 |
PDB Ligand | EVP |
- Oharra: Wikipediak ez du mediku aholkurik ematen. Tratamendua behar duzula uste baduzu, jo ezazu sendagilearengana.
Banaketa azkarreko zelula osasuntsu batzuetan ere eragin dezake, hala nola odolaren, digestio-aparatuaren edo ilearen zeluletan, eta, beraz, albo-ondorio kaltegarriak ere sortzen ditu.
Etoposidoa 1983an merkaturatu zuten.[1]
Erreferentziak
- (Ingelesez) Fischer, Janos; Ganellin, C. Robin. (2006). Analogue-based Drug Discovery. John Wiley & Sons, 489 or. ISBN 9783527607495..
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.